Cyber Resilience Act guidance raises the stakes for connected product suppliers

Tern plc

The latest Cyber Resilience Act guidance makes the direction of travel clear for connected product manufacturers. Security now has to be built in from the start, maintained through the life of the product and backed by clear processes for risk management, vulnerability handling and ongoing support.

Companies can no longer treat security as a box-ticking exercise at launch. They need to show that products can stay secure after deployment, through updates, configuration changes, new integrations and extended use in the field. That raises the bar for execution and increases the importance of scalable security operations.

This is especially relevant in IoT and OT markets, where products often stay in service for years and depend on complex supply chains, third-party software and remote services. In that environment, weak processes create risk over time. Manual controls, fragmented systems and assumptions of trust become harder to defend when regulation expects continuous oversight.

Security decisions have to reflect how products work in the real world, including where they are deployed, what data they process, what systems they connect to and which threats they are likely to face. For businesses operating in connected-device markets, this points to the value of stronger device identity, trusted credentials and secure communications. Without those foundations, it becomes harder to enforce policy, manage updates securely or demonstrate that cyber risks are under control.

Tern plc (LON:TERN) backs exciting, high growth IoT innovators in Europe. They provide support and create a genuinely collaborative environment for talented, well-motivated teams.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

Tern Plc announces 90% take-up of Open Offer

Tern Plc has received valid acceptances for 50.9 million Open Offer Shares, representing approximately 90% of the shares available. The fully underwritten offer will raise approximately £509,368 before expenses, with admission of the new shares expected on 24 September 2026.

Talking Medicines moves to capture pharma demand for better patient intelligence

Tighter US pharma advertising rules could increase demand for patient intelligence, supporting the relevance of Talking Medicines’ DrugVoice platform.

Tern portfolio company Talking Medicines launches ‘Intent to Prescribe’ DrugVoice application

Talking Medicines has launched a new DrugVoice application combining its Message Resonance Score™ with near-real-time point-of-care data to help pharmaceutical companies assess links between HCP message alignment and prescribing intent.

Device Authority targets secure digital infrastructure for smart ports

Device Authority's Smart, Green Port Blueprint shows how secure device management can support the wider rollout of connected infrastructure across modern ports.

Talking Medicines highlights strategic signals emerging across the GLP-1 consumer market

GLP-1 consumers are increasingly weighing access, affordability, quality, clinical oversight and treatment support, creating new strategic considerations across the wider life sciences market.

Tern Plc launches £509,368 underwritten Open Offer

Tern Plc has announced an underwritten Open Offer to raise approximately £509,368 through the issue of 56.6 million shares at 0.90p each. Qualifying shareholders may subscribe for one new share for every 16 shares held, with the offer closing on 22 September 2026.

Search